Skip to main content

Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX)

Tipranks - Tipranks - Tue Feb 24, 7:32AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and BioNTech SE (BNTX – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Ascendis Pharma (ASND)

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma today and set a price target of $256.00. The company’s shares closed last Friday at $225.00.

According to TipRanks.com, Skor is a 5-star analyst with an average return of 21.1% and a 65.4% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crinetics Pharmaceuticals, and Monopar Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $290.36 average price target, representing a 26.0% upside. In a report issued on February 14, TipRanks – Google also upgraded the stock to Buy with a $240.00 price target.

See today’s best-performing stocks on TipRanks >>

BioNTech SE (BNTX)

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE today and set a price target of $134.00. The company’s shares closed last Friday at $110.15.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 12.0% and a 60.8% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Crispr Therapeutics AG. ;'>

BioNTech SE has an analyst consensus of Strong Buy, with a price target consensus of $143.80.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).